Caregen Co., Ltd.
214370.KQ
Get informed when a big investor buys or sells
+ FollowMarket Cap$2.04T
Close$
$631.74
98.4% downside
Current Fair Value
98.4% downsideOvervalued by 98.4% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $2.04 Trillion |
|---|---|
| Enterprise Value | $2.04 Trillion |
| Dividend Yield | $400.00 (0.96%) |
| Earnings per Share | $411 |
| Beta | 0.7 |
| Outstanding Shares | 48,871,000 |
Return
| Return on Equity | 12.30% |
|---|---|
| Return on Assets | 11.15% |
| Return on Invested Capital | 9.55% |
Valuation & Multiples
| P/E Ratio | 76.18 |
|---|---|
| PEG | -745.13 |
| Price to Sales | 26.01 |
| Price to Book Ratio | 8.91 |
| Enterprise Value to Revenue | 27.21 |
| Enterprise Value to EBIT | 92.88 |
| Enterprise Value to Net Income | 75 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 14, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
$27.00 B
Average shareholder expectationNext Earnings Call
Expected Date
November 6, 2026
EPS Estimate
$138.60
Average shareholder expectationRevenue Estimate
$16.50 B
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Caregen Co., Ltd.
198 employees
CEO: Yong-Ji Chung Caregen Co., Ltd. is primarily involved in the creation and development of biomimetic peptides. The company operates through distinct business segments, each catering to specific markets. Its Professional Therapy division engineers medic...